van der Graaf WT - Search Results

1

Modulation of death receptor pathways in oncology.

de Vries EG, Timmer T, Mulder NH, van Geelen CM, van der Graaf WT, Spierings DC, de Hooge MN, Gietema JA, de Jong S. de Vries EG, et al. Among authors: van geelen cm, van der graaf wt. Drugs Today (Barc). 2003;39 Suppl C:95-109. Drugs Today (Barc). 2003. PMID: 14988748 Review.

2

In vitro and in vivo modulation of multi-drug resistance with amiodarone.

van der Graaf WT, de Vries EG, Uges DR, Nanninga AG, Meijer C, Vellenga E, Mulder PO, Mulder NH. van der Graaf WT, et al. Int J Cancer. 1991 Jun 19;48(4):616-22. doi: 10.1002/ijc.2910480422. Int J Cancer. 1991. PMID: 1646180

3

Mitoxantrone: bluebeard for malignancies.

van der Graaf WT, de Vries EG. van der Graaf WT, et al. Anticancer Drugs. 1990 Dec;1(2):109-25. Anticancer Drugs. 1990. PMID: 2151849

4

Dose escalation of dacarbazine combined with interferon alpha-2a, G-CSF and ondansetron in patients with metastatic melanoma.

Buter J, Sleijfer DT, Willemse PH, van der Graaf WT, de Vries EG, Schraffordt Koops H, Mulder NH. Buter J, et al. Among authors: van der graaf wt. Anticancer Res. 1994 May-Jun;14(3B):1325-8. Anticancer Res. 1994. PMID: 7520681 Clinical Trial.

5

Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.

Mulder NH, van der Graaf WT, Willemse PH, Koops HS, de Vries EG, Sleijfer DT. Mulder NH, et al. Among authors: van der graaf wt. Br J Cancer. 1994 Oct;70(4):681-3. doi: 10.1038/bjc.1994.372. Br J Cancer. 1994. PMID: 7522510 Free PMC article. Clinical Trial.

6

High-dose methotrexate, vincristine and cisplatin as salvage treatment for relapsed non-seminomatous germ-cell cancer.

Sleijfer S, Van der Graaf WT, Willemse PH, De Vries EG, Schraffordt Koops H, Mulder NH. Sleijfer S, et al. Among authors: van der graaf wt. Anticancer Res. 1995 May-Jun;15(3):1039-42. Anticancer Res. 1995. PMID: 7544087 Clinical Trial.

7

Serotonin metabolism following platinum-based chemotherapy combined with the serotonin type-3 antagonist tropisetron.

Schröder CP, van der Graaf WT, Kema IP, Groenewegen A, Sleijfer DT, de Vries EG. Schröder CP, et al. Among authors: van der graaf wt. Cancer Chemother Pharmacol. 1995;36(6):477-82. doi: 10.1007/BF00685797. Cancer Chemother Pharmacol. 1995. PMID: 7554039

8

Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer.

Veldhuis GJ, Willemse PH, Sleijfer DT, van der Graaf WT, Groen HJ, Limburg PC, Mulder NH, de Vries EG. Veldhuis GJ, et al. Among authors: van der graaf wt. J Clin Oncol. 1995 Oct;13(10):2585-93. doi: 10.1200/JCO.1995.13.10.2585. J Clin Oncol. 1995. PMID: 7595711 Clinical Trial.

9

Phase II study of intraperitoneal cisplatin plus systemic etoposide as second-line treatment in patients with small volume residual ovarian cancer.

de Jong RS, Willemse PH, Boonstra H, de Vries EG, van der Graaf WT, Sleijfer DT, van der Zee AG, Mulder NH. de Jong RS, et al. Among authors: van der graaf wt, van der zee ag. Eur J Cancer. 1995;31A(5):709-13. doi: 10.1016/0959-8049(94)00516-8. Eur J Cancer. 1995. PMID: 7640042 Clinical Trial.

10

Long-term results of induction- and intensification chemotherapy supported with autologous bone marrow reinfusion in patients with disseminated or T4 breast cancer.

Mulder NH, Dolsma WV, Mulder PO, De Vries EG, Willemse PH, Sleijfer DT, Hospers GA, Van der Graaf WT. Mulder NH, et al. Among authors: van der graaf wt. Anticancer Res. 1995 Jul-Aug;15(4):1565-8. Anticancer Res. 1995. PMID: 7654046 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

640 results

Search Page

Filters